Sava Infond D.O.O. Biomarin Pharmaceutical Inc Transaction History
Sava Infond D.O.O.
- $640 Billion
- Q2 2025
A detailed history of Sava Infond D.O.O. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Sava Infond D.O.O. holds 3,250 shares of BMRN stock, worth $167,245. This represents 0.03% of its overall portfolio holdings.
Number of Shares
3,250
Previous 3,250
-0.0%
Holding current value
$167,245
Previous $230 Million
22.24%
% of portfolio
0.03%
Previous 0.04%
Shares
1 transactions
Others Institutions Holding BMRN
# of Institutions
690Shares Held
186MCall Options Held
1.31MPut Options Held
1.1M-
Black Rock Inc. New York, NY22.7MShares$1.17 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.6MShares$956 Million0.02% of portfolio
-
Primecap Management CO Pasadena, CA15.8MShares$812 Million0.71% of portfolio
-
Dodge & Cox San Francisco, CA15.1MShares$777 Million0.5% of portfolio
-
Viking Global Investors LP12.3MShares$632 Million2.14% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $9.56B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...